Can you take Bosutinib with Dihydroxyaluminum sodium carbonate?
1 drug interaction and 18 additional warnings found for the following 2 drugs:
- bosutinib
- dihydroxyaluminum sodium carbonate
Drug interactions
Moderate drug interactions
Moderate:
dihydroxyaluminum sodium carbonate bosutinib
Applies to: dihydroxyaluminum sodium carbonate and bosutinib
Bosutinib and dihydroxyaluminum sodium carbonate should not be taken orally at the same time. Products that can decrease acid levels in the stomach may interfere with the absorption of bosutinib and reduce its effectiveness. You should take dihydroxyaluminum sodium carbonate at least 2 hours before or 2 hours after the dose of bosutinib. Contact your doctor if your condition worsens. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:
dihydroxyaluminum sodium carbonate Food/Lifestyle
Applies to: dihydroxyaluminum sodium carbonate
Citrate, or citric acid, can increase the absorption of dihydroxyaluminum sodium carbonate. This may lead to elevated blood levels of aluminum, particularly in individuals with reduced kidney function, since aluminum is primarily eliminated by the kidneys. Excess aluminum may deposit and cause problems in various tissues including bone, brain, heart, liver, muscles, and spleen. Over time, weak bones, bone pain, fractures, skeletal deformity, brain disorders, and anemia may develop. Talk to your doctor before using dihydroxyaluminum sodium carbonate if you have kidney impairment or are on hemodialysis. You should avoid or limit the consumption of citrate-containing foods and beverages (e.G., soft drinks, citrus fruits, fruit juices) during treatment with dihydroxyaluminum sodium carbonate. Be aware that some effervescent and dispersible drug formulations may also contain citrate and should be restricted as well. Even if you do not have kidney problems, it may be best to separate the dosing of dihydroxyaluminum sodium carbonate and citrate-containing products by 2 to 3 hours. Talk to a healthcare professional if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
When dihydroxyaluminum sodium carbonate is taken during enteral nutrition therapy (tube feeding), the tube may get clogged. Therefore, dihydroxyaluminum sodium carbonate should not be mixed with or given after high-protein tube feedings. The dose should be separated from the feeding by as much as possible, and the tube should be thoroughly flushed before administration of the dose.
Moderate food/lifestyle interactions
Moderate:
bosutinib Food/Lifestyle
Applies to: bosutinib
Bosutinib should be taken with a meal to help with its absorption. Do not consume grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with bosutinib unless directed otherwise by your doctor. Grapefruit juice can significantly increase the blood levels of bosutinib. You may be more likely to experience side effects such as nausea, vomiting, abdominal pain, diarrhea, liver damage, and impaired bone marrow function resulting in low numbers of different types of blood cells, which can increase the risk of anemia, bleeding problems, and infections. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
16 potential interactions Applies to: 14 conditions, including High Blood Pressure, Heart Failure, Diarrhea, Fluid Retention, and Liver Disease.
Bone Marrow Depression/Low Blood Counts
Moderate:
bosutinib
Bosutinib has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.
Thrombocytopenia, aplastic anemia, agranulocytosis, and neutropenia occur with BCR-ABL tyrosine kinase inhibitors. Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression. A complete blood count should be performed every 1 to 2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated. To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.
Cardiovascular Conditions and Disorders
Moderate:
bosutinib
Bosutinib has a moderate potential interaction with Cardiovascular Conditions and Disorders.
Cardiovascular events (including arterial vascular occlusive events, peripheral arterial occlusive disease, and ischemic cerebrovascular events) have been reported in patients receiving BCR-ABL tyrosine kinase inhibitors. Patients should seek immediate medical attention if acute signs or symptoms of cardiovascular events occur. Cardiovascular status should be evaluated, and cardiovascular risk factors should be monitored and actively managed during treatment.
Dehydration
Moderate:
bosutinib
Bosutinib has a moderate potential interaction with Dehydration.
Adequate hydration might be necessary during therapy with bosutinib as diarrhea, nausea, vomiting, and abdominal pain occur with treatment. Monitor and manage patients using standards of care, including antidiarrheals, antiemetics, and fluid replacement. To manage gastrointestinal toxicity, withhold, dose reduce, or discontinue bosutinib as necessary.
Diarrhea
Moderate:
bosutinib
Bosutinib has a moderate potential interaction with Diarrhea.
Adequate hydration might be necessary during therapy with bosutinib as diarrhea, nausea, vomiting, and abdominal pain occur with treatment. Monitor and manage patients using standards of care, including antidiarrheals, antiemetics, and fluid replacement. To manage gastrointestinal toxicity, withhold, dose reduce, or discontinue bosutinib as necessary.
Fluid Retention
Moderate:
bosutinib
Bosutinib has a moderate potential interaction with Fluid Retention.
Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema. Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure. Monitor and manage patients using standards of care. Interrupt, reduce dose or discontinue therapy as necessary.
Heart Failure
Moderate:
bosutinib
Bosutinib has a moderate potential interaction with Heart Failure.
Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema. Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure. Monitor and manage patients using standards of care. Interrupt, reduce dose or discontinue therapy as necessary.
Moderate:
dihydroxyaluminum sodium carbonate
Dihydroxyaluminum sodium carbonate has a moderate potential interaction with Heart Failure.
The sodium content of antacids may be significant. Patients with hypertension, congestive heart failure, or those on restricted sodium diets should use an antacid with a low sodium content.
High Blood Pressure
Moderate:
dihydroxyaluminum sodium carbonate
Dihydroxyaluminum sodium carbonate has a moderate potential interaction with High Blood Pressure.
The sodium content of antacids may be significant. Patients with hypertension, congestive heart failure, or those on restricted sodium diets should use an antacid with a low sodium content.
Hypernatremia
Moderate:
dihydroxyaluminum sodium carbonate
Dihydroxyaluminum sodium carbonate has a moderate potential interaction with Hypernatremia.
The sodium content of antacids may be significant. Patients with hypertension, congestive heart failure, or those on restricted sodium diets should use an antacid with a low sodium content.
Intestinal Obstruction
Major:
dihydroxyaluminum sodium carbonate
Dihydroxyaluminum sodium carbonate has a major potential interaction with Intestinal Obstruction.
Aluminum containing antacids may produce constipation, which may lead to intestinal obstruction. Osteomalacia and hypophosphatemia may be produced in patients with renal dysfunction who are not receiving dialysis. Patients with renal dysfunction, intestinal obstruction, osteomalacia, or hypophosphatemia should use antacids with low or no aluminum content.
Liver Disease
Moderate:
bosutinib
Bosutinib has a moderate potential interaction with Liver Disease.
Bosutinib is primarily metabolized by the CYP 450 3A4. Therapy with bosutinib should be administered cautiously in patients with hepatic impairment and the starting dose should be 200 mg daily in patients with baseline hepatic impairment. The manufacturer recommends performing hepatic enzyme tests monthly for the first three months of bosutinib treatment and as clinically indicated. In patients with transaminase elevations, monitor liver enzymes more frequently. Withhold, reduce dose, or discontinue bosutinib as necessary.
Phosphate Imbalance
Major:
dihydroxyaluminum sodium carbonate
Dihydroxyaluminum sodium carbonate has a major potential interaction with Phosphate Imbalance.
Aluminum containing antacids may produce constipation, which may lead to intestinal obstruction. Osteomalacia and hypophosphatemia may be produced in patients with renal dysfunction who are not receiving dialysis. Patients with renal dysfunction, intestinal obstruction, osteomalacia, or hypophosphatemia should use antacids with low or no aluminum content.
Pleural Effusion
Moderate:
bosutinib
Bosutinib has a moderate potential interaction with Pleural Effusion.
Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema. Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure. Monitor and manage patients using standards of care. Interrupt, reduce dose or discontinue therapy as necessary.
Renal Dysfunction
Major:
dihydroxyaluminum sodium carbonate
Dihydroxyaluminum sodium carbonate has a major potential interaction with Renal Dysfunction.
Aluminum containing antacids may produce constipation, which may lead to intestinal obstruction. Osteomalacia and hypophosphatemia may be produced in patients with renal dysfunction who are not receiving dialysis. Patients with renal dysfunction, intestinal obstruction, osteomalacia, or hypophosphatemia should use antacids with low or no aluminum content.
Moderate:
bosutinib
Bosutinib has a moderate potential interaction with Renal Dysfunction.
An on-treatment decline in estimated glomerular filtration rate (eGFR) has occurred in patients treated with bosutinib. The manufacturer recommends reducing the bosutinib starting dose in patients with severe (CrCl) less than 30 mL/min) or moderate (CrCl 30 to 50 mL/min) renal impairment at baseline. Consider dose adjustment in patients with baseline and treatment emergent renal impairment. It is recommended to monitor patients for renal function at baseline and during therapy with bosutinib, with particular attention to those patients who have preexisting renal impairment or risk factors for renal dysfunction.
Vomiting
Moderate:
bosutinib
Bosutinib has a moderate potential interaction with Vomiting.
Adequate hydration might be necessary during therapy with bosutinib as diarrhea, nausea, vomiting, and abdominal pain occur with treatment. Monitor and manage patients using standards of care, including antidiarrheals, antiemetics, and fluid replacement. To manage gastrointestinal toxicity, withhold, dose reduce, or discontinue bosutinib as necessary.
Report options
More resources
bosutinib
A total of 597 drugs are known to interact with bosutinib.
- Bosutinib is in the drug class BCR-ABL tyrosine kinase inhibitors.
- Bosutinib is used to treat Chronic Myelogenous Leukemia.
dihydroxyaluminum sodium carbonate
A total of 227 drugs are known to interact with dihydroxyaluminum sodium carbonate.
- Dihydroxyaluminum sodium carbonate is in the drug class antacids.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.